Digital Outcome Measurement to Improve Care for Patients With Immune-Mediated Inflammatory Diseases: Protocol for the IMID Registry
- PMID: 36995758
- PMCID: PMC10131723
- DOI: 10.2196/43230
Digital Outcome Measurement to Improve Care for Patients With Immune-Mediated Inflammatory Diseases: Protocol for the IMID Registry
Abstract
Background: Despite enormous clinical improvements, due to better management strategies and the availability of biologicals, immune-mediated inflammatory diseases (IMIDs) still have a significant impact on patients' lives. To further reduce disease burden, provider- as well as patient-reported outcomes (PROs) should be taken into account during treatment and follow-up. Web-based collection of these outcomes generates valuable repeated measurements, which could be used (1) in daily clinical practice for patient-centered care, including shared decision-making; (2) for research purposes; and (3) as an essential step toward the implementation of value-based health care (VBHC). Our ultimate goal is that our health care delivery system is completely aligned with the principles of VBHC. For aforementioned reasons, we implemented the IMID registry.
Objective: The IMID registry is a digital system for routine outcome measurement that mainly includes PROs to improve care for patients with IMIDs.
Methods: The IMID registry is a longitudinal observational prospective cohort study within the departments of rheumatology, gastroenterology, dermatology, immunology, clinical pharmacy, and outpatient pharmacy of the Erasmus MC, the Netherlands. Patients with the following diseases are eligible for inclusion: inflammatory arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, uveitis, Behçet disease, sarcoidosis, and systemic vasculitis. Generic and disease-specific (patient-reported) outcomes, including adherence to medication, side effects, quality of life, work productivity, disease damage, and activity, are collected from patients and providers at fixed intervals before and during outpatient clinic visits. Data are collected and visualized through a data capture system, which is linked directly to the patients' electronic health record, which not only facilitates a more holistic care approach, but also helps with shared decision-making.
Results: The IMID registry is an ongoing cohort with no end date. Inclusion started in April 2018. From start until September 2022, a total of 1417 patients have been included from the participating departments. The mean age at inclusion was 46 (SD 16) years, and 56% of the patient population is female. The average percentage of filled out questionnaires at baseline is 84%, which drops to 72% after 1 year of follow-up. This decline may be due to the fact that the outcomes are not always discussed during the outpatient clinic visit or because the questionnaires were sometimes forgotten to set out. The registry is also used for research purposes and 92% of the patients with IMIDs gave informed consent to use their data for that.
Conclusions: The IMID registry is a web-based digital system that collects provider- and PROs. The collected outcomes are used to improve care for the individual patient with an IMID and facilitate shared decision-making, and they are also used for research purposes. The measurement of these outcomes is an essential step toward the implementation of VBHC.
International registered report identifier (irrid): DERR1-10.2196/43230.
Keywords: IMID; dermatology; digital system; disease; gastroenterology; immune-mediated inflammatory diseases; immunology; inflammatory; mHealth; medicine; patient; patient-reported outcomes; quality of life; rheumatology; tool; value-based health care; web-based; web-based tool.
©Agnes E M Looijen, Reinier C A van Linschoten, Jan-Dietert Brugma, Dirk Jan Hijnen, Pascal H P de Jong, P Hugo M van der Kuy, Jan A M van Laar, C Janneke van der Woude, Annelieke Pasma. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 30.03.2023.
Conflict of interest statement
Conflicts of Interest: CJvdW received grants and fee for advisory boards and presentations from Pfizer, Abbvie, Celltrion, Falk Benelux, Takeda, Janssen, and Ferring outside the submitted work. DJH is an investigator for AbbVie, Almirall, LEO Pharma, AstraZeneca, Novartis, and Sanofi and a consultant for Abbvie, Sanofi, LEO Pharma, AstraZeneca, Novartis, Janssen, Pfizer, and Lilly.
References
-
- Kuek A, Hazleman BL, Ostör AJK. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J. 2007;83(978):251–260. doi: 10.1136/pgmj.2006.052688. https://europepmc.org/abstract/MED/17403952 83/978/251 - DOI - PMC - PubMed
-
- McInnes IB, Gravallese EM. Immune-mediated inflammatory disease therapeutics: past, present and future. Nat Rev Immunol. 2021;21(10):680–686. doi: 10.1038/s41577-021-00603-1. https://europepmc.org/abstract/MED/34518662 10.1038/s41577-021-00603-1 - DOI - PMC - PubMed
-
- Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, McInnes IB, Sepriano A, van Vollenhoven RF, de Wit M, Aletaha D, Aringer M, Askling J, Balsa A, Boers M, den Broeder AA, Buch MH, Buttgereit F, Caporali R, Cardiel MH, De Cock D, Codreanu C, Cutolo M, Edwards CJ, van Eijk-Hustings Y, Emery P, Finckh A, Gossec L, Gottenberg J, Hetland ML, Huizinga TWJ, Koloumas M, Li Z, Mariette X, Müller-Ladner Ulf, Mysler EF, da Silva JAP, Poór G, Pope JE, Rubbert-Roth A, Ruyssen-Witrand A, Saag KG, Strangfeld A, Takeuchi T, Voshaar M, Westhovens R, van der Heijde D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685–699. doi: 10.1136/annrheumdis-2019-216655. https://air.unimi.it/handle/2434/750456 annrheumdis-2019-216655 - DOI - PubMed
-
- van der Heijde D, Ramiro S, Landewé R, Baraliakos X, Van den Bosch F, Sepriano A, Regel A, Ciurea A, Dagfinrud H, Dougados M, van Gaalen F, Géher P, van der Horst-Bruinsma I, Inman RD, Jongkees M, Kiltz U, Kvien TK, Machado PM, Marzo-Ortega H, Molto A, Navarro-Compàn V, Ozgocmen S, Pimentel-Santos FM, Reveille J, Rudwaleit M, Sieper J, Sampaio-Barros P, Wiek D, Braun J. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978–991. doi: 10.1136/annrheumdis-2016-210770. https://core.ac.uk/reader/79554506?utm_source=linkout annrheumdis-2016-210770 - DOI - PubMed
-
- Gossec L, Baraliakos X, Kerschbaumer A, de Wit M, McInnes I, Dougados M, Primdahl J, McGonagle DG, Aletaha D, Balanescu A, Balint PV, Bertheussen H, Boehncke W, Burmester GR, Canete JD, Damjanov NS, Kragstrup TW, Kvien TK, Landewé RBM, Lories RJU, Marzo-Ortega H, Poddubnyy D, Rodrigues Manica SA, Schett G, Veale DJ, Van den Bosch FE, van der Heijde D, Smolen JS. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):700–712. doi: 10.1136/annrheumdis-2020-217159. http://ard.bmj.com/lookup/pmidlookup?view=long&pmid=32434812 annrheumdis-2020-217159 - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous